1067651-24-4

Basic information

• Product Name: N-[(1S,2S,4R)-4-benzylcarbamoyl-1-(3,5-difluorophenoxymethyl)-2-hydroxy-4-methoxybutyl]-5-(methanesulfonyl(methyl)amino)-N'-((R)-1-phenyl-ethyl)-isophthalamide
• CAS NO: 1067651-24-4
• Molecular Weight: 752.836
• Mol File: 1067651-24-4.mol

Chemical Properties

• CAS DataBase Reference: N-[(1S,2S,4R)-4-benzylcarbamoyl-1-(3,5-difluorophenoxymethyl)-2-hydroxy-4-methoxybutyl]-5-(methanesulfonyl(methyl)amino)-N'-((R)-1-phenyl-ethyl)-isophthalamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-[(1S,2S,4R)-4-benzylcarbamoyl-1-(3,5-difluorophenoxymethyl)-2-hydroxy-4-methoxybutyl]-5-(methanesulfonyl(methyl)amino)-N'-((R)-1-phenyl-ethyl)-isophthalamide(1067651-24-4)
• EPA Substance Registry System: N-[(1S,2S,4R)-4-benzylcarbamoyl-1-(3,5-difluorophenoxymethyl)-2-hydroxy-4-methoxybutyl]-5-(methanesulfonyl(methyl)amino)-N'-((R)-1-phenyl-ethyl)-isophthalamide(1067651-24-4)

Safety Data

• Hazardous Substances Data: 1067651-24-4(Hazardous Substances Data)

Upstream product

• 1067652-51-0 C₂₀H₂₄F₂N₂O₄ 
• 695215-92-0 3-[methyl(methylsulfonyl)amino]-5-((1R)-1-phenylethylaminocarbonyl)benzoate acid 

Relevant articles and documents

Design and synthesis of potent and selective BACE-1 inhibitor

Highly potent BACE-1 protease inhibitors have been developed from an inhibitors containing a hydroxyethylene (HE) core displaying aryloxymethyl or benzyloxymethyl P1 side chain and a methoxy P1′ side chain. The target molecules were synthesized in good overall yields from chiral carbohydrate starting materials. The inhibitors show high BACE-1 potency and good, selectivity against cathepsin D, where the most potent inhibitor furnishes BACE-1 Ki ? 1 nM and displays > 1000-fold selectivity over cathepsin D.

AMIDE DERIVATIVES AS INHIBITORS OF ASPARTYL PROTEASES

The invention provides compounds of the formula (I). N-oxides, addition salts, quaternary amines, metal complexes, stereochemically isomeric forms and metabolites thereof, wherein W is H,C 1-C 6 alkyl, C 3-C 6 cycloalkyl, aryl or heterocyclyl; Q is aryl or heterocyclyl; A is a five or six membered saturated, partially unsaturated or aromatic ring; D is (II) or (III) the other variables are as defined in the specification. The compounds of the invention are inhibitors of BACE and are among other things useful for the treatment and/or prevention of conditions associated with BACE activity such as Alzheimer's disease.